We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · January 12, 2021

Modified Glasgow Prognostic Score as a Predictor of Prognosis in mRCC Treated With Nivolumab

Clinical Genitourinary Cancer

 

Additional Info

Clinical Genitourinary Cancer
Modified Glasgow Prognostic Score as a Predictor of Prognosis in Metastatic Renal Cell Carcinoma Treated With Nivolumab
Clin Genitourin Cancer 2020 Nov 10;[EPub Ahead of Print], R Fujiwara, K Takemura, M Fujiwara, T Yuasa, S Yasuoka, Y Komai, N Numao, S Yamamoto, J Yonese

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading